论文部分内容阅读
[目的]观察青芪散对免疫损伤小鼠的免疫调节作用。[方法]中药复方制剂青芪散小、中、大3个剂量治疗冻干卡介苗(BCG)加脂多糖(LPS)免疫性肝损伤小鼠,与迈普新(Tα1)对照,观察其对淋巴细胞亚群、白细胞介素2(IL2)及肝脏病理的影响。[结果]青芪散中剂量组显著降低CD8+,提高CD3+、CD4+及CD4+/CD8+比值,与Tα1组比较差异有统计学意义(P<0.05);对肝组织病理学影响,中剂量组与Tα1组比较稍优,但无统计学意义(P>0.05)。[结论]青芪散有明确的免疫调节作用。
[Objective] To observe the immunoregulatory effect of Qingqi Powder on immunocompromised mice. [Methods] Traditional Chinese medicine compound preparations Qinglan San small, medium and large doses were used to treat lyophilized BCG and lipopolysaccharide (LPS) immunological liver injury mice and compared with Maipuxin (Tα1) to observe its effect on lymph Cell subsets, interleukin 2 (IL2), and liver pathology. [Results] The middle dose group of Qingqi Powder significantly reduced CD8+, increased the ratio of CD3+, CD4+, and CD4+/CD8+, which was significantly different from that of Tα1 group (P<0.05); the pathological effects on liver tissue, middle dose group and Tα1 The group was slightly superior but not statistically significant (P>0.05). [Conclusion] Qingyi Powder has a clear immunomodulatory effect.